- Conditions
- Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic Alterations
- Interventions
- DCC-2701 tablet
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 3,364
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- PF-08046037, sasanlimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pemetrexed disodium
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Interventions
- ADCE-T02
- Drug
- Lead sponsor
- Adcendo ApS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Rogers, Arkansas • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Solid Tumor
- Interventions
- 5-ALA
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumor
- Interventions
- SLC-3010, Gemcitabine
- Drug · Combination Product
- Lead sponsor
- Selecxine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Detroit, Michigan • Oklahoma City, Oklahoma
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-102 with a light tracer dose of [14C]FTD, TAS-102 with a light tracer dose of [14C] TPI, TAS-102 tablets
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- LCL161, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Interventions
- EP31670
- Drug
- Lead sponsor
- Epigenetix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
- Conditions
- Solid Tumor
- Interventions
- BHV-1530, Cemiplimab
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
- Interventions
- Palbociclib Oral Product, TAS-116
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Solid Tumors, Advanced Cancer, Cancer, Neoplasms
- Interventions
- rigosertib sodium
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Tumors
- Interventions
- Dasatinib + Ketoconazole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Tampa, Florida • Nashville, Tennessee + 1 more
- Conditions
- Tumors, Neoplasms, Cancer
- Interventions
- APS001F, Flucytosine (5-FC), 10% maltose
- Drug
- Lead sponsor
- Anaeropharma Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Houston, Texas
- Conditions
- Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
- Interventions
- FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
- Drug
- Lead sponsor
- Flare Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
- Conditions
- Advanced Solid Tumor
- Interventions
- YL201, YL201 and atezolizumab
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Interventions
- NC410
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- BIIB021 and Food, BIIB0121 and Antacid
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Encinitas, California • San Antonio, Texas
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- HER2-positive Solid Cancers
- Interventions
- MT-5111 (experimental study drug)
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Alamitos, California + 18 more
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Interventions
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Biological
- Lead sponsor
- Anza Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California
- Conditions
- Advanced Solid Tumor, BRAF V600 Mutation
- Interventions
- ABM-1310, Cobimetinib
- Drug
- Lead sponsor
- ABM Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- San Francisco, California • Stanford, California • Miami, Florida + 4 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio